We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Low-Profile Marker Advances Breast Conservation Therapy

By HospiMedica International staff writers
Posted on 08 Mar 2017
Print article
Image: The BioZorb LP device (Photo courtesy of Focal Therapeutics).
Image: The BioZorb LP device (Photo courtesy of Focal Therapeutics).
A novel bioabsorbable marker implanted during oncoplastic surgery helps delineate the surgical cavity for radiation treatment and long-term monitoring.

The Focal Therapeutics BioZorb low profile (LP) device has a unique three-dimensional (3D) open-spiral design that incorporates six titanium clips placed in a fixed arrangement, providing specific landmarks of the surgical site for treatment planning, delivery, and follow-up. As in the original BioZorb design, the LP model is sutured directly to the tissues surrounding the cavity where the tumor was removed. The bioabsorbable implant dissolves in the body over the course of a year or more, while the titanium marker clips remain in place.

The BioZorb is especially useful when there is no visible residual seroma, a condition encountered during radiation therapy (RT) planning that makes it very difficult to identify the target region. The 3D marker may also assist with patient positioning during treatment, as well as advanced treatment techniques such as image-guided RT and image-based tracking of the lumpectomy site during respiratory motion. The BioZorb LP device, in contrast to the original BioZorb, was designed for use in smaller breasts, in peripheral areas of the breast, and in locations with less surrounding tissue.

“Everyone understands the need for delivering more personalized, targeted and precise medical care. These new designs allow me to offer the BioZorb marker to more of my breast cancer patients,” said Alison Laidley, MD, of Texas Breast Specialists, who was among the first physicians to use BioZorb LP. “Our radiation oncologists who oversee post-surgical radiation treatment have embraced this technology. We have also seen that patients support the idea of minimizing toxicity to surrounding healthy tissues during their radiation treatment.”

Breast conserving therapy (BCT) refers to moderate-dose RT to eradicate any microscopic residual disease left over following breast-conserving surgery. The goals of BCT are to provide the survival equivalent of mastectomy, a cosmetically acceptable breast, and a low rate of recurrence in the treated breast. The success of BCT is also contingent upon moderate-dose RT to eliminate subclinical foci of disease in the ipsilateral breast.

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Vibrating Mesh Nebulizer
Aerogen Solo

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.